Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.
Executive Summary
Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
You may also be interested in...
Clinical Update (02/2007)
A brief summary of recent clinical developments impacting the medical device industry, including limb regeneration, NIH's research plan for Type I diabetes, heart failure and statins; and new glaucoma research.
AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
Reformulation has Ruled in Neurology Dealmaking--Until Now
The big deals in other therapeutic areas focus on novel molecules, in neurology, most focus on formulations of existing molecules. There just hasn't been a lot of novel material that's piqued the interest of licensees, at least in part because of the risk of developing novel neurology compounds. But as Windhover's Therapeutic Alliances: Neuroscience conference showed, much of the new, licensable pipeline is very novel indeed.